Bioventus Inc-A 2026年季度报告

FORM 10-Q (Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended March 28, 2026OR☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from ____________ to ____________Commission File Number: 001-37844 BIOVENTUS INC. (Exact Name of Registrant as Specified in Its Charter) 81-0980861 (919) 474-6700(Registrant’s Telephone Number, Including Area Code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to suchfiling requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submitsuch files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, oran emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. Largeacceleratedfiler☐Accelerated filer☒Non-accelerated filer☐Smallerreportingcompany☐Emerging growth company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☒ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of April 27, 2026, there were 67,748,048 shares of Class A common stock outstanding and 15,786,737 shares of Class B common stockoutstanding. BIOVENTUS INC. TABLE OF CONTENTS PART I. FINANCIAL INFORMATION Item 1.Financial Statements (Unaudited)Consolidated Condensed Statements of Operations and Comprehensive Income (Loss) for the three monthsended March28, 2026 and March29, 2025Consolidated Condensed Balance Sheets as of March28, 2026 and December31, 2025Consolidated Condensed Statements of Changes in Stockholders’ Equity for the three months ended March28,2026 and March29, 2025Consolidated Condensed Statements of Cash Flows for the three months ended March28, 2026 and March29,2025Notes to the Unaudited Consolidated Condensed Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations22Item 3.Quantitative and Qualitative Disclosures About Market Risk29Item 4.Controls and Procedures29PART II. OTHER INFORMATIONItem 1.Legal Proceedings30Item 1A.Risk Factors32Item 2.Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities32Item 3.Defaults Upon Senior Securities32Item 4.Mine Safety Disclosures32Item 5.Other Information32Item 6.Exhibits32Signature34 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS As used in this Quarterly Report on Form 10-Q, unless expressly indicated or the context otherwise requires, references to“Bioventus,” “we,” “us,” “our,” the “Company,” and similar references refer to Bioventus Inc. and its consolidated subsidiaries,including Bioventus LLC (“BV LLC”). This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 21E of the SecuritiesExchange Act of 1934, as amended (“Exchange Act”), and Section 27A of the Securities Act of 1933, as amended (“Securities Act”),concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for ourbusiness operations and financial performance and condition. Any statements contained herein that are not statements of historicalfacts may be deemed to be forward-looking statements including, without limitation, statements concerning: our future financialresults and liquidity; our business strategy, position and operations; and expected sales trends, opportunities, market position andgrowth. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,”“contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,”“positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future eventsand future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements containthese words. Forward-looking statement